July 2023

Mejora de los resultados informados por los pacientes y de la productividad laboral después de 3 años de tratamiento con Ustekinumab o un inhibidor del factor de necrosis tumoral en pacientes con artritis psoriásica: Resultados del estudio de mundo real PsABio

Arthritis Res Ther. 2023 Jun 23;25(1):109. doi: 10.1186/s13075-023-03058-y

Results from the 3-year PsABio study demonstrated that, generally, ustekinumab and TNFi treatment led to an improvement in PROs. In coming to this conclusion, researchers aimed to evaluate the real-world effect of ustekinumab or a TNFi on PRO and their association with effectiveness endpoints in PsA patients over 3 years.

Keywords:

March 2023

Diferencias específicas de Género en pacientes con Artritis Psoriásica Recibiendo Ustekinumab o Inhibidores del Factor de Necrosis Tumoral: Datos de Mundo Real

Rheumatology (Oxford). 2023 doi: 10.1093/rheumatology/kead089

These real-world data from PsABio on gender differences suggest that, at the start of biologic treatment, females have a worse clinical picture of PsA than males. In coming to these conclusions and others, this study sought to investigate effects of gender on disease characteristics and treatment impact in patients with PsA.

Keywords: